SPHRF (Starpharma Holdings) Beginning Cash Position: $10.24 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPHRF Starpharma Holdings Ltd SPHRF
51 GF Score
Price $0.51
GF Value $0.34
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Beginning Cash Position?

Starpharma Holdings SPHRF 51 Beginning Cash Position is $10.24 Mil as of Dec. 2025. GuruFocus rates SPHRF with a GF Score™ of 51/100 and a GF Value™ of $0.34 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Starpharma Holdings's Beginning Cash Position for the quarter that ended in Dec. 2025 was $10.24 Mil.

Starpharma Holdings's quarterly Beginning Cash Position declined from Dec. 2024 ($14.80 Mil) to Jun. 2025 ($13.20 Mil) and declined from Jun. 2025 ($13.20 Mil) to Dec. 2025 ($10.24 Mil).

Starpharma Holdings's annual Beginning Cash Position declined from Jun. 2023 ($33.50 Mil) to Jun. 2024 ($23.36 Mil) and declined from Jun. 2024 ($23.36 Mil) to Jun. 2025 ($15.21 Mil).

Starpharma Holdings Beginning Cash Position Related Terms

Starpharma Holdings Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Beginning Cash Position Chart

Starpharma Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.98 42.52 33.50 23.36 15.21

Starpharma Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.55 21.34 14.80 13.20 10.24
SPHRF
51GF Score
Starpharma Holdings Ltd SPHRF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $10.24 Mil mean?
Starpharma Holdings (SPHRF) has a Beginning Cash Position of $10.24 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Starpharma Holdings and its competitors.
Is Starpharma Holdings' Beginning Cash Position too high?
Starpharma Holdings' current Beginning Cash Position is $10.24 Mil. Overall, Starpharma Holdings has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Beginning Cash Position compare to VRTX and REGN?
Starpharma Holdings' Beginning Cash Position of $10.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current Beginning Cash Position is $10.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (SPHRF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.34, compared to a current price of $0.51 — trading 48.9% above its estimated fair value. The current Beginning Cash Position is $10.24 Mil. Starpharma Holdings' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Starpharma Holdings (SPHRF), the current Beginning Cash Position is $10.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (SPHRF) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of $0.51 is trading 48.9% above its estimated GF Value™ of $0.34. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for SPHRF:

  • Beginning Cash Position: $10.24 Mil
  • GF Value™: $0.34 vs. price of $0.51 (48.9% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the SPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
51GF Score

Get the complete analysis for SPHRF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.51
Price
$0.34
GF Value